Insider Transactions in Q1 2023 at Genelux Corp (GNLX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2023
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+50.0%
|
-
|
|
Feb 17
2023
|
Gabe Woodward Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+19.28%
|
-
|
|
Feb 17
2023
|
Mary Mirabelli |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+50.0%
|
-
|
|
Feb 17
2023
|
James L Tyree |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|
|
Feb 17
2023
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
900
+50.0%
|
-
|
|
Feb 17
2023
|
Qian Zhang Associate VP, Research |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+4.13%
|
-
|
|
Feb 17
2023
|
John Thomas |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+1.84%
|
-
|
|
Feb 17
2023
|
Joseph Cappello VP, Pharmaceutical Development |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|
|
Feb 17
2023
|
Tony Yu VP, Clinical Trial Operations |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+5.36%
|
-
|
|
Feb 17
2023
|
Doug Samuelson Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
3,600
+50.0%
|
-
|
|
Jan 30
2023
|
Aladar Szalay |
BUY
Conversion of derivative security
|
Indirect |
1,000,000
+32.87%
|
-
|
|
Jan 30
2023
|
Gabe Woodward Director |
BUY
Conversion of derivative security
|
Indirect |
8,176
+50.0%
|
-
|
|
Jan 30
2023
|
Gabe Woodward Director |
BUY
Conversion of derivative security
|
Direct |
3,186
+50.0%
|
-
|
|
Jan 30
2023
|
John Thomas |
BUY
Conversion of derivative security
|
Direct |
470,000
+50.0%
|
-
|
|
Jan 26
2023
|
Qian Zhang Associate VP, Research |
BUY
Open market or private purchase
|
Indirect |
200
+50.0%
|
$1,200
$6.25 P/Share
|